Disruptive Pharma Seeks Partner for Oral Drug Development
Disruptive Pharma is seeking a partner for oral drug development at BIO-Europe.
Related stories
Indivior Reports Third-Quarter 2026 Revenue of $356 Million
Revenue rose 13.4% from $314 million a year earlier. Net income increased to $137 million from $42 million, and diluted EPS rose to $1.12 from $0.33.
M impact | EQUITY | Oct 29, 2026, 12:21 PM UTC
CACI erhält US-Armee-Auftrag über bis zu 185 Millionen US-Dollar
CACI erhielt einen Auftrag der US-Armee mit einem Wert von bis zu 185 Millionen US-Dollar.
M impact | EQUITY | Oct 29, 2026, 12:21 PM UTC
Midea Group Q3 Net Profit Rises More Than Two-Tenths Year Over Year
Midea Group said third-quarter net profit rose by more than two-tenths year over year, its fastest quarterly growth rate in a year and a half.
M impact | EQUITY | Oct 29, 2026, 12:21 PM UTC
Merck Opens South Korean Bioprocessing Center With Investment Exceeding €300 Million
Merck opened a bioprocessing center in South Korea after an investment exceeding €300 million.
M impact | EQUITY | Oct 29, 2026, 12:21 PM UTC
Coherus Reports 89% Confirmed Response Rate in Esophageal Cancer Trial
Coherus Oncology reported an 89% confirmed response rate for a tagmokitug combination in a first-line esophageal cancer trial.
M impact | EQUITY | Oct 29, 2026, 12:21 PM UTC
Merck Opens South Korea Bioprocessing Center With Major Investment
Merck opened a bioprocessing center in South Korea.
M impact | EQUITY | Oct 29, 2026, 12:21 PM UTC